Ace Therapeutics is a trusted partner in preclinical liver research, offering end-to-end solutions to address critical challenges in liver failure pathogenesis studies and therapeutic development. We empower researchers and biopharma partners to accelerate the development of effective liver failure therapeutics through scientifically rigorous preclinical research.
Overview of Liver Failure
Liver failure is a life-threatening clinical syndrome characterized by severe hepatic dysfunction, classically presenting with the triad of jaundice, coagulopathy, and hepatic encephalopathy. This complex condition arises from diverse pathogenic mechanisms and etiological factors:
- Infectious Pathogens: Hepatotropic viruses (notably HBV, HCV)
- Toxic Insults: Alcohol, drug and chemical/toxin induced hepatotoxicity
- Immune-mediated Damage: Autoimmune hepatitis variants
- Metabolic Disorders: Genetic defects in hepatic metabolism
- Neoplastic Processes: Primary or metastatic hepatic malignancies
Fig. 1 Insights into of pathophysiology of acute on chronic liver failure. (Br VK, et al., 2023)
The development of appropriate animal models is crucial for advancing liver failure research. We specialize in developing customized liver failure models that simulate the complex pathophysiology involving hepatocyte injury, metabolic dysregulation, inflammatory responses, and multi-organ crosstalk, thereby facilitating meaningful translational research. Our custom models include:
- Chemically Induced Models of Liver Failure
- Surgical Animal Models of Liver Failure
- Immunologic Models of Liver Failure
- Viral Induced Models of Liver Failure
- Genetic Models of Liver Failure
Drug Development Services for Liver Failure
Drug Target Identification and Validation Services
- Transcriptomic and Single Cell Sequencing Analysis
Through integrated transcriptomic and single-cell sequencing approaches, we characterize the dysregulation of critical liver failure-associated pathways to systematically identify and validate novel therapeutic targets for liver failure intervention.
- Metabolomics Analysis
We employ advanced metabolomic platforms to quantify pathological alterations in key plasma metabolites (e.g., bile acids, ammonia, and short-chain fatty acids), enabling the development of targeted interventions for metabolic pathway modulation.
Drug Screening Services for Liver Failure
- Drug Screening in Cellular Models
Using both primary hepatocytes and established hepatocyte lines (e.g., HepG2, Huh7), we establish liver injury cell models through LPS/D-GalN or APAP. The hepatoprotective effect is comprehensively assessed by quantitative analysis of hepatocellular integrity markers, apoptotic progression, and mitochondrial function.
- High-Throughput Screening
Using sensitive detection platforms, we conduct automated large-scale screening of diverse chemical libraries against defined molecular targets for quantitative activity characterization and lead compound identification.
Preclinical Efficacy and Mechanism Study Services
- Hepatocyte Protection Assay
We employ well-characterized in vitro hepatocyte injury models (induced by LPS/D-GalN, APAP, or hypoxia-reoxygenation [H/R] challenge) to systematically assess drug candidates through standardized quantitative assays, such as cell viability, apoptotic activity, and mitochondrial function.
- Pharmacodynamic Evaluation in Acute Liver Failure Models
Using clinically relevant acute liver injury models (induced by LPS/D-GalN, APAP or partial hepatectomy), we evaluate drug efficacy through multiparametric analysis including hepatic function markers, coagulation status, and comprehensive histopathological evaluation of liver tissues.
- Anti-inflammatory & Anti-apoptotic Mechanism Studies
Our advanced analytical platform employs integrated transcriptomic, proteomic, and systems biology approaches to systematically elucidate compound mechanisms of action at molecular, cellular, and organ system levels. Through quantitative assessment of inflammatory pathway modulation, apoptotic regulation, and hepatic regenerative capacity, we guide therapeutic development and optimize drug candidates.
Ace Therapeutics has a team of professionals in the field of liver disease research. We will develop appropriate service program for liver failure drug development according to your needs. If you would like to learn more about our services, please do not hesitate to contact us.
Reference
- Br, V.K.; Sarin, S.K. Acute-on-chronic liver failure: Terminology, mechanisms and management. Clin Mol Hepatol. 2023, 29(3):670-689.
Related Services
Our products and services are for research use only and can not be used for diagnostic or other purposes.
